Latest Ofatumumab Stories
IMBRUVICA data presented at the American Society of Hematology Annual Meeting show 79 percent of CLL patients with del 17p were progression-free at 12 months SAN FRANCISCO and RARITAN, N.J.,
Data Show 84% Progression-Free Survival Rate at One Year and Improvement in Quality of Life SAN FRANCISCO, Dec. 8, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
- Note: This press release corresponds to abstracts 627 and 1998. SAN FRANCISCO, Dec. 8, 2014 /PRNewswire/ -- New IMBRUVICA(®) (ibrutinib) Phase II data announced by Pharmacyclics, Inc.
Results Show Durable Responses in High Risk Patient Population MARTINSRIED, Germany, MUNICH and MONROVIA, Calif., Dec.
U.S.-Based Registry Will Enhance Clinical Knowledge of and Explore Treatment Options for CLL Patients SUNNYVALE, Calif., Dec. 5, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
SUNNYVALE, Calif., Oct. 17, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
- IMBRUVICA Net Product Revenue Increased to $109.5 million for the Second Quarter of 2014 - SUNNYVALE, Calif., July 31, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
Approval based on Phase 3 RESONATE data with statistically significant improvements in progression-free and overall survival HORSHAM, Pa., July 28, 2014 /PRNewswire/ -- The U.S.
Previously Treated Chronic Lymphocytic Leukemia (CLL) Based on Statistically Significant Progression-Free and Overall Survival Benefits SUNNYVALE, Calif., July 28, 2014 /PRNewswire/ -- Pharmacyclics,
SUNNYVALE, Calif., July 25, 2014 /PRNewswire/ -- Pharmacyclics, Inc.